KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM, L3
Announces Second Quarter 2025 Financial Results and Business Updates
Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
Shareholder votes
Annual Report to Security Holders
Financial Results, Reg. FD
Announces Full Year 2024 Financial Results and Provides Business Updates
Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
News, Legal Opinion
Q2
Q1
FY 2024
Q3
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
PRER14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload